Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
The price of Allogene Therapeutics Inc (NASDAQ: ALLO) closed at $1.45 in the last session, down -0.68% from day before closing price of $1.46. In other words, the price has decreased by -$0.68 from its previous closing price. On the day, 2.59 million shares were traded.
Ratios:
We take a closer look at ALLO’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 9.71 and its Current Ratio is at 9.71. In the meantime, Its Debt-to-Equity ratio is 0.23 whereas as Long-Term Debt/Eq ratio is at 0.21.
On March 14, 2025, Citizens JMP Upgraded its rating to Mkt Outperform which previously was Mkt Perform but kept the price unchanged to $5.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jun 10 ’25 when MESSEMER DEBORAH M. bought 36,885 shares for $1.42 per share.
Yoshiyama Annie sold 9,601 shares of ALLO for $13,537 on Apr 21 ’25. The SVP, Finance now owns 130,663 shares after completing the transaction at $1.41 per share. On Apr 21 ’25, another insider, Yoshiyama Annie, who serves as the Officer of the company, bought 9,601 shares for $1.41 each.
Stock Price History:
Over the past 52 weeks, ALLO has reached a high of $3.78, while it has fallen to a 52-week low of $0.86. The 50-Day Moving Average of the stock is 7.83%, while the 200-Day Moving Average is calculated to be -29.02%.
Shares Statistics:
A total of 218.60M shares are outstanding, with a floating share count of 149.47M. Insiders hold about 31.67% of the company’s shares, while institutions hold 66.00% stake in the company.
